Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages 1556-1568

  Perez, Edith A ^a   Awada, Ahmad ^b   O'Shaughnessy, Joyce ^c   Rugo, Hope S ^d   Twelves, Chris ^e   Im, Seock Ah ^f   Gómez Pardo, Patricia ^g   Schwartzberg, Lee S ^h   Diéras, Veronique ⁱ   Yardley, Denise A ^j   Potter, David A ^k   Mailliez, Audrey ^l   Moreno Aspitia, Alvaro ^a   Ahn, Jin Seok ^m   Zhao, Carol ⁿ   Hoch, Ute ⁿ   Tagliaferri, Mary ⁿ   Hannah, Alison L ^o   Cortes, Javier ^g,p  

^a MAYO CLINIC   (United States)

^b JULES BORDET INSTITUTE   (Belgium)

^c TEXAS ONCOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f Seoul National University Hospital   (South Korea)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h WEST CLINIC   (United States)

ⁱ INSTITUT CURIE   (France)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^l CENTRE OSCAR LAMBRET   (France)

^m Sungkyunkwan University School of Medicine   (South Korea)

ⁿ NEKTAR THERAPEUTICS   (United States)

^o Ramon y Cajal University Hospital ^*  (United States)

^p HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; ERIBULIN; ETIRINOTECAN PEGOL; GEMCITABINE; IXABEPILONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BRIDGED COMPOUND; FUSED HETEROCYCLIC RINGS; MACROGOL DERIVATIVE; TAXANE; TAXOID;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLURRED VISION; BREAST CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UPPER ABDOMINAL PAIN; VERY ELDERLY; VOMITING; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; PHYSICIAN;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CAPECITABINE; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PHYSICIANS; POLYETHYLENE GLYCOLS; TAXOIDS;

EID: 84960964225     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00332-0     Document Type: Article

References (17)

1. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 2 National Comprehensive Cancer Network, (accessed May 15, 2015). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
2. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014, 25:1871-1888.
3. Hoch U, Staschen C-M, Johnson R, Eldon MA Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 2014, 74:1125-1137.
4. Bai J, Zhou Z, Tang H, et al. Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA. J Liposome Res 2013, 23:1-10.
5. Rothenberg ML, Kuhn JG, Rodriguez FI, et al. Phase 1 dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 2001, 12:1631-1641.
6. Jameson GS, Hamm JT, Weiss GJ, et al. Multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 2013, 19:268-278.
7. Von HoffDD, Jameson GS, Borad MJ, et al. First phase I trial of NKTR-102 (PEG irinotecan) reveals early evidence of broad antitumor activity in three schedules. Eur J Cancer 2008, 6:595.
8. Awada A, Garcia AA, Chan S, et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol 2013, 14:1216-1225.
9. DeMets DL, Lan KKG Interim analysis: the alpha spending function approach. Stat Med 1994, 13:1341-1352.
10. Cortes J, Levy C, Demidchik Y, et al. A randomized phase III study of vinflunine versus an alkylating agent of physician's choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid. J Clin Oncol 2015, 33:1031.
11. Sparano JA, Vrodoliak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28:3256-3263.
12. Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010, 122:409-418.
13. Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
14. Baselga J, Costa F, Gomez H, et al. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials 2013, 14:228.
15. Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015, 33:594-601.
16. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377:914-923.
17. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008, 26:1987-1992.